Related Experiment Video
Updated: May 20, 2026
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Targeting GD2 with CAR-T Cell Therapy in Neuroblastoma: Updates, Challenges, and Future Perspectives
Hortense Alliot1,2, Pierre Machy1, Marc-David Leclair2
1Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, F, Nantes, 44000, France.
Purpose Of Review:
High-risk neuroblastoma remains a challenging pediatric cancer, with survival rates lagging despite advances in multimodal therapy. This review aims to critically synthesize recent advances in GD2-directed chimeric antigen receptor (CAR) T cell therapy for neuroblastoma and to highlight its potential to improve long-term outcomes.
Recent Findings:
In early-phase trials of GD2-directed CAR-T cell therapy for relapsed or refractory neuroblastoma, no dose-limiting toxicities were observed. Objective responses ranged from 6% to 33%, with durable complete remissions reported beyond 10 years. Stable disease occurred in up to 55% of patients. Cytokine release syndrome was reported in 0-90% of cases, generally mild, and neurotoxicity was rare. CAR-T cell expansion and trafficking to tumor sites have been demonstrated in several studies, although they remain variable and often limited in solid tumor settings. GD2-directed CAR-T cell therapy demonstrates limited but measurable clinical activity, particularly in minimal residual disease settings, with an overall acceptable safety profile. Continued innovation in CAR design and integration into multimodal strategies may improve long-term outcomes for this aggressive pediatric cancer.
Insights
Chimeric antigen receptor (CAR) T cell therapy targeting GD2 shows promise for high-risk neuroblastoma, demonstrating durable remissions and an acceptable safety profile in early trials. Further innovation may enhance outcomes for this challenging pediatric cancer.
Area of Science:
- Pediatric Oncology
- Immunotherapy
- Cellular Therapy
Background:
- High-risk neuroblastoma presents a significant challenge in pediatric oncology.
- Current multimodal therapies offer limited long-term survival rates.
- GD2 is a validated target for neuroblastoma therapy.
Purpose of the Study:
- To review recent advancements in GD2-directed chimeric antigen receptor (CAR) T cell therapy for neuroblastoma.
- To assess the potential of CAR T cell therapy to improve outcomes in pediatric neuroblastoma.
Main Methods:
- Systematic review of early-phase clinical trials involving GD2-directed CAR T cell therapy.
- Analysis of objective response rates, duration of response, and safety profiles.
- Evaluation of CAR T cell expansion, trafficking, and clinical activity in solid tumors.
Main Results:
- Early trials reported objective responses from 6% to 33% and durable complete remissions exceeding 10 years.
- Cytokine release syndrome and neurotoxicity were generally mild and rare.
- CAR T cell therapy demonstrated measurable clinical activity, especially in minimal residual disease settings, with an acceptable safety profile.
Conclusions:
- GD2-directed CAR T cell therapy shows potential for treating high-risk neuroblastoma.
- Continued innovation in CAR design and multimodal integration is crucial for improving long-term outcomes.
- This therapy offers a promising avenue for patients with relapsed or refractory neuroblastoma.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy